PHENYLEPHRINE

US Approved OTC

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C9H13NO2
Molecular Weight	167.205
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CNC[C@H](O)C1=CC(O)=CC=C1

InChI

InChIKey=SONNWYBIRXJNDC-VIFPVBQESA-N

InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C9H13NO2
Molecular Weight	167.205
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00388
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf and https://www.drugs.com/pro/phenylephrine-and-chlorpheniramine-tablets.html

Phenylephrine is a powerful vasoconstrictor. It is used as a nasal decongestant and cardiotonic agent. Phenylephrine is a postsynaptic α1-receptor agonist with little effect on β-receptors of the heart. Parenteral administration of phenylephrine causes a rise in systolic and diastolic pressures, a slight decrease in cardiac output, and a considerable increase in peripheral resistance; most vascular beds are constricted, and renal, splanchnic, cutaneous, and limb blood flows are reduced while coronary blood flow is increased. Phenelephrine also causes pulmonary vessel constriction and subsequent increase in pulmonary arterial pressure. Vasoconstriction in the mucosa of the respiratory tract leads to decreased edema and increased drainage of sinus cavities. In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Phenylephrine appears to act similarly on all three receptor subtypes. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of the α1-receptor activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Phenylephrine produces its local and systemic actions by acting on α1-adrenergic receptors peripheral vascular smooth muscle. Stimulation of the α1-adrenergic receptors results in contraction arteriolar smooth muscle in the periphery. Phenylephrine decreases nasal congestion by acting on α1-adrenergic receptors in the arterioles of the nasal mucosa to produce constriction; this leads to decreased edema and increased drainage of the sinus cavities. Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Alpha-1a adrenergic receptor 66 Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00388	Agonist 2662	55.0 nM [EC50]
Alpha-1b adrenergic receptor 44 Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25813897	Agonist 2662	5.9 nM [EC50]
Alpha-1d adrenergic receptor 36 Target ID: CHEMBL326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8831777	Agonist 2662	154.88 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypotension 28 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf	Primary		Approved 8360	VAZCULEP Approved Use VAZCULEP (phenylephrine hydrochloride) is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Launch Date -5.05007997E11
Eye diseases 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	Diagnostic		Approved 8360	Phenylephrine Hydrochloride Ophthalmic Solution Approved Use Indicated to dilate the pupil Launch Date -9.7839363E11

C_max

Value	Dose	Analyte	Population
2959 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4492 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1354 pg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
2346 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3900 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
955.8 pg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.93 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.64 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.89 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/26267590	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PHENYLEPHRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	Disc. AE: Ischemic colitis... AEs leading to discontinuation/dose reduction: Ischemic colitis (acute) Sources: https://pubmed.ncbi.nlm.nih.gov/33062792
40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	Disc. AE: Chest pain, Jaw pain... Other AEs: Nervous system disorders, Headache... AEs leading to discontinuation/dose reduction: Chest pain (1 patient) Jaw pain (1 patient) Other AEs: Nervous system disorders (3.6%) Headache (2.7%) Gastrointestinal disorders (8%) Dry mouth (2.7%) Nausea (3.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	Other AEs: Eye pain, Blurred vision... Other AEs: Eye pain Blurred vision Photophobia Allergic conjunctivitis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
250 ug single, intravenous Recommended Dose: 250 ug Route: intravenous Route: single Dose: 250 ug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf

AEs

AE	Significance	Dose	Population
Ischemic colitis	acute Disc. AE	10 mg 1 times / day multiple, oral Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33062792	unhealthy, 34 years n = 1 Health Status: unhealthy Age Group: 34 years Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/33062792
Chest pain	1 patient Disc. AE	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Jaw pain	1 patient Disc. AE	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Dry mouth	2.7%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Headache	2.7%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Nausea	3.6%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Nervous system disorders	3.6%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Gastrointestinal disorders	8%	40 mg 6 times / day multiple, oral Highest studied dose Dose: 40 mg, 6 times / day Route: oral Route: multiple Dose: 40 mg, 6 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26143019	unhealthy, 37.5 years (range: 19.0 - 77.0 years) n = 112 Health Status: unhealthy Condition: Seasonal Allergic Rhinitis Age Group: 37.5 years (range: 19.0 - 77.0 years) Sex: M+F Population Size: 112 Sources: https://pubmed.ncbi.nlm.nih.gov/26143019
Allergic conjunctivitis		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Blurred vision		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Eye pain		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf
Photophobia		10 % 3 times / day multiple, ophthalmic Recommended Dose: 10 %, 3 times / day Route: ophthalmic Route: multiple Dose: 10 %, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	healthy, > 1 year Health Status: healthy Age Group: > 1 year Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
		CYP1A2 689

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1673	inducer 1542 Sources: https://pubmed.ncbi.nlm.nih.gov/16510159/ Page: 10.0	yes

PubMed

Title	Date	PubMed
Altered baroreflex control of heart rate in bradykinin B2-receptor knockout mice.	1999 Dec	10614985
[An unusual episode of angina].	1999 Mar	10389447
Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy.	2000 Aug	10900171
Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release.	2000 Dec 1	11102496
Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors.	2000 Feb 15	10660688
Bupivacaine inhibits baroreflex control of heart rate in conscious rats.	2000 Jan	10638917
Fine structure and plasticity of barosensitive neurons in the nucleus of solitary tract.	2000 Jul 3	10861511
Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.	2000 Jun	10888249
Mesenteric dysfunction after cardiopulmonary bypass: role of complement C5a.	2000 Mar	10750764
Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits.	2000 Mar 7	10704171
Heparin-mediated hypotension associated with cardiac surgery.	2000 Sep	10960424
Effects of salt intake and angiotensin II on vascular reactivity to endothelin-1.	2001 Feb	11160616
Reflex cardiovascular responses originating in exercising muscles of mice.	2001 Feb	11160056
Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility.	2001 Feb	11159833
Nitric oxide-mediated arteriolar dilation after endothelial deformation.	2001 Feb	11158970
Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control.	2001 Feb	11158964
Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1.	2001 Feb	11158304
Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.	2001 Feb	11158043
Heat, but not mechanical hyperalgesia, following adrenergic injections in normal human skin.	2001 Feb 1	11166966
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.	2001 Feb 16	11179201
Ras regulates NFAT3 activity in cardiac myocytes.	2001 Feb 2	11044444
Nitric oxide contributes to vascular smooth muscle relaxation in contracting fast-twitch muscles.	2001 Feb 7	11161004
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.	2001 Feb 9	11071898
Detection and characterization of cholinergic oscillatory control in the forehead microvasculature in response to systemic alpha-agonist infusion in healthy volunteers.	2001 Jan	11162204
A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors.	2001 Jan	11159691
Activity of cardiorespiratory networks revealed by transsynaptic virus expressing GFP.	2001 Jan	11152744
Involvement of Ca2+ -activated K+ channels in ginsenosides-induced aortic relaxation in rats.	2001 Jan	11152372
Effect of dietary vitamin E supplementation on vascular reactivity of thoracic aorta in streptozotocin-diabetic rats.	2001 Jan	11150923
Increased dilator response to heptanol and octanol in aorta from DOCA-salt-hypertensive rats.	2001 Jan	11150920
In vivo measurement of pulsewave velocity in small vessels using intravascular MR.	2001 Jan	11146486
Exercise attenuates alpha-adrenergic-receptor responsiveness in skeletal muscle vasculature.	2001 Jan	11133908
Catecholamine responses to alpha-adrenergic blockade during exercise in women acutely exposed to altitude.	2001 Jan	11133901
Should the angiotensin II antagonists be discontinued before surgery?	2001 Jan	11133595
Effects of acute and chronic hypertension on the labyrinthine barriers in rat.	2001 Jan	11124468
CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR.	2001 Jan	11124159
Acute hypertension inhibits thirst stimulated by ANG II, hyperosmolality, or hypovolemia in rats.	2001 Jan	11124154
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS.	2001 Jan	11124138
Endothelin and nitric oxide mediate reduced myogenic reactivity of small renal arteries from pregnant rats.	2001 Jan	11124127
Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction.	2001 Jan	11123195
Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle.	2001 Jan	11121374
Novel site-specific chemical delivery system as a potential mydriatic agent: formation of phenylephrine in the iris-ciliary body from phenylephrone chemical delivery systems.	2001 Jan	11064374
Receptor reserve analysis of the human alpha(2C)-adrenoceptor using.	2001 Jan 12	11164378
In vivo regulation of Na/Ca exchanger expression by adrenergic effectors.	2001 Mar	11179087
Regulation of slow wave frequency by IP(3)-sensitive calcium release in the murine small intestine.	2001 Mar	11171626
EDHF contributes to strain-related differences in pulmonary arterial relaxation in rats.	2001 Mar	11159029

Patents

Sample Use Guides

In Vivo Use Guide

VAZCULEP (phenylephrine hydrochloride) Injection, 10 mg/mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min.

Route of Administration: Intravenous

In Vitro Use Guide

The hypertrophic phenotype of neonatal rat cardiomyocyte cultures (cardiomyocyte size, sarcomeric organization, total protein synthesis, c-fos expression) mediated by phenylephrine (10 uM) was counteracted by the selective A1 receptor agonist

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:38:33 UTC 2023` Edited by `admin` on `Wed Jul 05 22:38:33 UTC 2023`
Record UNII	1WS297W6MV
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PHENYLEPHRINE

Official Name

English

J8.601K

Code

English

M-SYMPATHOL

Common Name

English

M-SYNEPHRINE

Common Name

English

AB-101 (PHENYLEPHRINE)

Code

English

(R)-PHENYLEPHRINE

Common Name

English

(-)-3 HYDROXY-.ALPHA.-((METHYLAMINO)METHYL)BENZENEMETHANOL

Systematic Name

English

PHENYLEPHRINE, (R)-

Common Name

English

PHENYLEPHRINE MINIMS

Brand Name

English

R(-)-MEZATON

Common Name

English

PHENYLEPHRINE [HSDB]

Common Name

English

(-)-1-(3-HYDROXYPHENYL)-2-METHYLAMINOETHANOL

Systematic Name

English

M-OXEDRINE

Common Name

English

Phenylephrine [WHO-DD]

Common Name

English

PHENYLEPHRINE [VANDF]

Common Name

English

PHENYLEPHRINE [MI]

Common Name

English

META-SYNEPHRINE

Common Name

English

phenylephrine [INN]

Common Name

English

M-SYMPATOL

Common Name

English

PHENYLEPHRINE [EP IMPURITY]

Common Name

English

PHENYLEPHRINE [EP MONOGRAPH]

Common Name

English

METASYNEPHRINE

Common Name

English

(-)-PHENYLEPHRINE

Common Name

English

PHENYLEPHRINE [MART.]

Common Name

English

Classification Tree Code System Code

LIVERTOX

773